加入收藏 繁體中文 English 网站地图
用户名: 密 码:
您现在的位置:首页 >> 主营业务 >> 内容

A Brief IntroDuction On GIPI

时间:2009-8-6 14:53:34

Guangzhou Institute of Pharmaceutical Industry (GIPI), established in 1972, is a key institute of pharmaceutical industry in South China. It has a relatively integrate research system for the development of pharmaceutical products and the correlative technology..

At present, GIPI consists of six departments, including pharmaceutical chemistry department , Guangzhou Research Center of Controlled Release Dosage Forms , natural and traditional Chinese medicine department, pharmaceutical analysis and quality control department, Non-clinical Drug Evaluation Center and animal Colony. GIPI has a main building with 10,000 square meters as experimental labs and administrative office. There are 120 employees in GIPI, including scientists, engineers, staffs, and workers.

Since 1980’s, GIPI has successfully developed processes for more than ten pharmaceutical bulk materials, for instance, Metoprolol, Propafenone, Amiodarone, Tolperisone, 5-Aminosalicylic, Hymecromone, Fexofenadine and so on. Most of them have been put into production in domestic companies and marketed. It also completed total synthesis of tetrahydropalmatine, a very effective analgesic, hypnotic alkaloid, in 1990’s. .

In 1990, we built Guangzhou Pharmaceutical R & D Center of Controlled Release Dosage Forms with great support from Guangzhou Scientific Committee and State Pharmaceutical Administration. Since the time, we have developed almost twenty extended release formulations and got Certificates of New Drugs or Approvals from the State Food and Drug Administration (SFDA) for them. Most of them have been licensed to pharmaceutical companies, including those in Hong Kong. The typical extended release products are as follows: SR Fexofenadine and Pseudoephedrine Cap., CR Metoprolol Tab., CR Diltiazem Cap., SR Metformin Tab. CR Salbutamol Cap., SR Naproxen Tab., SR Ibuprofen Tab., SR Theopylline Tab., and Mesalazine Enteric Tab. and so on. Up till now, GIPI possesses two Chinese Patents for formulation technologies.

Its “Non-clinical Drug Evaluation Center ” is one of the key GLP labs for drug safety evaluation in China, recognized and approved by SFDA. The center has completed more than hundred safety evaluation projects of the items, including new candidate compounds, pharmaceutical bulk materials and formulations, produced with the technologies developed in China. All research reports of the safety evaluation we prepared have been accepted by the Center for Drug Evaluation, SFDA. The drug evaluation center also accepts contact research on pharmacodynamic studies.

We are feeding various standard animals for experiments in the animal colony, covering an area of over 90,000 square meters, in the outskirt of the city. Usually, the amount of beagle dogs on hand quantity is around 1,000 -2,000 in it. Besides for our experimental use, we also provide some of the animals to other institutes, universities or pharmaceutical companies. There is National Seed Center Of Beagle Dog and Guangdong Provincial Beagle Dog Idioplasmic Resource Center in the colony. Zoologists in it are engaged in the research of reproduction and standardization of dogs.

In general, GIPI has completed more than forty import projects from Authorities of State, or Province, or Guangzhou City besides the contract research from pharmaceutical companies since 1970’s. It has been granted more than twenty prizes and honors for them from State Scientific Committee, Ministry, Provincial and municipal governments and so on.
 

              TEL:(8620)84412127、84241726       FAX:(8620)84237584  

作者: 来源:Guangzhou Institute Of Pharmaceutical Industry
  • 上一篇:联系我们
  • 下一篇:技术转让
  • 本类推荐
    本类固顶
    • 没有
  • 广州医药研究总院有限公司 © 2014 版权所有 All Rights Resverved.
  • 建议使用IE5.5以上版本1024*768分辨率浏览 [管理入口]
  • 网站地图 粤ICP备11107135号-1